Fenzol Fenbendazole 500

What is Fenbendazole 500

• Fenbendazole is an anthelmintic (dewormer) from the benzimidazole class. It works against many kinds of internal parasites (nematodes, some cestodes/tapeworms, and helminths) in animals.

• “Fenbendazole 500” normally refers to a formulation containing 500 mg of fenbendazole per unit (e.g. tablet/bolus) for veterinary use. E.g. one bolus (tablet) may contain 500 mg of active fenbendazole.

Product Examples / Approvals

• There is a veterinary tablet “PANACUR 500” for dogs containing 500 mg of fenbendazole per tablet. It is authorized in France.

• Many veterinary formulations (tablets, boluses, powders) exist in various strengths; 500 mg is a common one for larger animals or higher parasite burdens.

Safety, Toxicology & Regulatory Status

• According to European regulatory / veterinary sources: Fenbendazole is of low acute toxicity orally in animals.

• No evidence of genotoxicity; in long-term rodent studies, there was no carcinogenicity found.

• But for human safety: limited data. The “NOEL” (no observed effect level) in some animal (rat/dog) studies is high; but safety margins depend on species, dose, and duration.

• In Europe, human data suggests: single doses up to 2,000 mg, and repeated doses up to 500 mg/day for 10 days, did not result in serious adverse effects in limited settings. But such uses are outside mainstream approved indications.

What Is Not Known / What Is Controversial

• Use in humans for treating diseases other than parasitic infections is largely experimental or anecdotal. There are no large, well-controlled clinical trials showing safety & efficacy for uses such as cancer, viruses, or other off-label/investigational uses.

• The proper dosing, duration, interactions, and long-term safety in humans are not established.

• Products labeled for veterinary use may not meet pharmaceutical purity or manufacturing standards for human medications; risk of impurities, variable potency, formulation issues.

• Risk of liver effects, immune, or other adverse effects when used off-label in humans is possible.